SGLT2抑制剂作为胰岛素辅助治疗在1型糖尿病青少年中的随机对照试验
ATTEMPT试验为22周双盲随机安慰剂对照研究,纳入98例12-21岁1型糖尿病青少年,评估达格列净5 mg作为胰岛素辅助治疗的效果。达格列净较安慰剂降低mGFR 8.8 ml min-1 1.73 m-2,HbA1c降低0.47%,目标血糖范围内时间增加9.0%,体重降低2.8 kg,不良事件组间相似,达格列净组发生1例轻度DKA。
要点
- 达格列净较安慰剂降低mGFR 8.8 ml min-1 1.73 m-2(95%CI:-12.7至-4.8;P<0.0001)。
- 达格列净较安慰剂降低HbA1c 0.47%(95%CI:-0.66至-0.28),目标血糖范围内时间增加9.0%(95%CI:3.8-14.3)。
- 达格列净组发生1例轻度DKA,不良事件组间相似。
核心结论
- 在1型糖尿病青少年中,达格列净作为胰岛素辅助治疗可降低mGFR、改善血糖控制,并在联合酮体检测和风险缓解策略时是安全的。
研究设计与样本
- ATTEMPT试验为22周双盲随机安慰剂对照试验,纳入98例12-21岁1型糖尿病青少年(53%女性),随机分配至达格列净5 mg或安慰剂组,同时进行酮体监测和DKA风险缓解教育。
主要发现
- 达格列净较安慰剂降低mGFR 8.8 ml min-1 1.73 m-2(95%CI:-12.7至-4.8;P<0.0001),基线mGFR较高的参与者使用达格列净后衰减更明显(r:-0.58;P<0.0001)。
- 达格列净较安慰剂降低HbA1c 0.47%(95%CI:-0.66至-0.28),目标血糖范围内时间(血糖70-180 mg dl-1,4-10 mmol L-1)增加9.0%(95%CI:3.8-14.3)。
- 达格列净较安慰剂降低体重2.8 kg(95%CI:-3.7至-2.0),每日胰岛素总剂量(U kg-1)组间无差异。
- 不良事件组间相似,达格列净组发生1例轻度DKA。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sodium glucose co-transporter 2 inhibitors (SGLT2i) reduce the risk of chronic kidney disease (CKD) progression in type 2 diabetes, but their effects in type 1 diabetes (T1D) are not completely understood. ATTEMPT (Adolescent Type 1 Diabetes Treatment with SGLT2i for Hyperglycemia and Hyperfiltration Trial) is a 22-week, double-blind, randomized, placebo-controlled trial to assess dapagliflozin, as an adjunct to insulin, in youth with T1D. Ninety-eight participants (12-21 years of age, 53% female) were randomly assigned to dapagliflozin 5 mg or placebo alongside ketone monitoring and diabetic ketoacidosis (DKA) risk mitigation education. The primary outcome was change in measured glomerular filtration rate (mGFR) using iohexol clearance. Dapagliflozin reduced mGFR by 8.8 ml min-1 1.73 m-2 when compared to placebo (95% confidence interval (CI): -12.7 to -4.8; P < 0.0001), and participants with higher baseline mGFR experienced greater attenuation with dapagliflozin (r: -0.58; P < 0.0001). HbA1c decreased by 0.47% (95% CI: -0.66 to -0.28), and time in range (glucose levels 70-180 mg dl-1, 4-10 mmol L-1) increased by 9.0% (95% CI: 3.8-14.3). Body weight decreased by 2.8 kg (95% CI: -3.7 to -2.0) with dapagliflozin. No differences were observed with respect to total daily insulin dose (U kg-1). Adverse events were similar between groups, with one mild DKA case in the dapagliflozin group. In youth with T1D, dapagliflozin as an adjunct-to-insulin treatment reduced mGFR, improved glycemic control and was safe when combined with ketone testing and risk mitigation strategies. ClinicalTrials.gov: NCT04333823 .
引用
- Mahmud FH, Bjornstad P, Clarson C, et al. Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial. Nat Med. 2025. PMID: 40481206. doi:10.1038/s41591-025-03723-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。